巴瑞替尼治疗激素抵抗或复发免疫性血小板减少症的安全性与疗效:一项开放标签先导研究
这项开放标签单臂2期试验纳入35例对糖皮质激素及至少一种后续治疗无效、入组时血小板计数低于30×10^9/L的原发性免疫性血小板减少症成人患者,每日口服巴瑞替尼4 mg共6个月。6个月随访时20例(57.1%,95%CI 39.9–74.4)达持久缓解,初始缓解23例(65.7%);11例(31.4%)报告不良事件,6例(17.1%)发生感染。
要点
- 巴瑞替尼4 mg每日口服6个月,35例中20例(57.1%)达持久缓解,23例(65.7%)达初始缓解。
- 缓解者中位起效时间12天(IQR 6–20),中位血小板峰值94(IQR 72–128)×10^9/L。
- 11例(31.4%)报告不良事件,其中感染6例(17.1%),2例(5.7%)因不良事件停药。
核心结论
- 这项先导研究的证据提示,巴瑞替尼可能成为免疫性血小板减少症改善药物的新候选。
- 尚需未来研究验证巴瑞替尼在免疫性血小板减少症患者中的安全性、疗效和最佳剂量。
研究设计与样本
- 开放标签、单臂、2期试验(NCT05446831),探索巴瑞替尼治疗免疫性血小板减少症的安全性与疗效。
- 纳入成人原发性免疫性血小板减少症患者,须对糖皮质激素及至少一种后续治疗无效,入组时血小板计数低于30×10^9/L。
- 共入组35例,接受巴瑞替尼4 mg每日口服共6个月。
- 主要终点为6个月随访时的持久缓解。
主要发现
- 持久缓解20例(57.1%,95%CI 39.9–74.4),初始缓解23例(65.7%)。
- 缓解患者中位起效时间12天(IQR 6–20),中位血小板峰值94(IQR 72–128)×10^9/L。
- 27例延长观察的患者中,12例(44.4%)在停用巴瑞替尼后中位约20周内保持缓解。
- 11例(31.4%)报告不良事件,治疗期间感染6例(17.1%)。
- 因不良事件停药2例(5.7%)。
局限性
- 原文指出尚需未来研究验证巴瑞替尼在免疫性血小板减少症患者中的安全性、疗效和最佳剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with steroid-resistant or relapsed immune thrombocytopenia (ITP) suffer increased bleeding risk and impaired quality of life. Baricitinib, an oral Janus-associated kinases (JAK) inhibitor, could alleviate both innate and adaptive immune disorders without inducing thrombocytopenia in several autoimmune diseases. Accordingly, an open-label, single-arm, phase 2 trial (NCT05446831) was initiated to explore the safety and efficacy of baricitinib in ITP. Eligible patients were adults with primary ITP who were refractory to corticosteroids and at least one subsequent treatment, and had platelet counts below 30 × 109/L at enrolment. Participants received baricitinib 4 mg daily for 6 months. The primary endpoint was durable response at the 6-month follow-up. A total of 35 patients were enrolled. Durable response was achieved in 20 patients (57.1%, 95% confidence interval, 39.9 to 74.4), and initial response in 23 (65.7%) patients. For patients responding to baricitinib, the median time to response was 12 (IQR 6-20) days, and the median peak platelet count was 94 (IQR 72-128) × 109/L. Among the 27 patients undergoing extend observation, 12 (44.4%) remained responsive for a median duration of approximately 20 weeks after baricitinib discontinuation. Adverse events were reported in 11 (31.4%) patients, including infections in 6 (17.1%) patients during the treatment period. Treatment discontinuation due to an adverse event was reported in 2 (5.7%) patients. Evidence from this pilot study suggested that baricitinib might be a novel candidate for the armamentarium of ITP-modifying agents. Future studies are warranted to validate the safety, efficacy, and optimal dosing of baricitinib in patients with ITP.
引用
- Zhao P, An ZY, Fu HX, et al. Safety and efficacy of baricitinib in steroid-resistant or relapsed immune thrombocytopenia: An open-label pilot study. Am J Hematol. 2024. PMID: 38980207. doi:10.1002/ajh.27433
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。